法乐通治疗晚期乳腺癌临床总结  

Clinical trial of toremifene in postmenopausal patients with advanced breast cancer

作　　者：何小慧[1,2,3,4,5,6] 冯奉仪[1,2,3,4,5,6] 许立功 唐惟瑜[1,2,3,4,5,6] 何桂芬 江泽飞[1,2,3,4,5,6] 宋三泰 刘冬耕[1,2,3,4,5,6] 何友兼[1,2,3,4,5,6] 杨莹 周美珍[1,2,3,4,5,6] 

机构地区：[1]中国医学科学院中国协和医科大学肿瘤研究所肿瘤医院 [2]上海医科大学肿瘤医院 [3]北京307医院 [4]中山医科大学肿瘤医院 [5]北京复兴医院 [6]北京医院

出　　处：《癌症》1999年第3期309-310,335,共3页Chinese Journal of Cancer

摘　　要：目的：考察法乐通治疗晚期绝经后乳腺癌的疗效及其不良反应。方法：法乐通一线治疗每日一次６０ｍｇ口服，二线治疗每日一次１２０ｍｇ口服。结果：共６０例，有效率１８３％。一线治疗１８例，有效率３３３％。二线治疗４２例，有效率１１９％。淋巴结和骨转移疗效较好，肝转移、肺转移及胸壁转移也有一定疗效。一线治疗较二线治疗、未用内分泌治疗较曾用内分泌治疗、绝经时间长（≥１０年）较绝经时间短（＜１０年）以及疗后无瘤间期长（≥５年）较疗后无瘤间期短（＜５年）疗效好，不良反应轻微，主要为恶心、纳差。结论：法乐通是治疗晚期绝经后乳腺癌有效和安全的抗雌激素抗肿瘤新药。Objective: To observe the efficacy and toxicities of toremifene in postmenopausal patients with advanced breast cancer. Methods: From September 1996 to March 1998,60 postmenopausal patients with advanced breast cancer were enrolled in this study.Toremifene(TOR)has been assessed both as initial(firstline)and secondline treatment following failure of other measures such as hormonal treatment and/or cytotoxic chemotherapy.The patients with firstline were assigned to receive daily 60 mg TOR.The patients with secondline were assigned to receive daily 120 mg TOR. Results: The overall response rates(complete response and partial response)was 183%in all patients.The overall response rate was 333%in 18 patients as firstline treatment.The overall response rate was 119%in 42 cases patients as secondline treatment.The response rates of lympohatic and bone metastases were higher.The response rates inpatients with firstline treatment,no prior hormone treatment and longer menopausal time(10 years) were higher than that in patients with secondline treatment,prior hormone treatment and shorter menopausal time(< 10 years)(not statistically different).The response rates in patients with longer diseasefree interval(5 years) were higher than that in patients with shorter disseasefree interval(< 5 yeays)(statisically dlifferent).The most common adverse effects were nause and anorexia. Conclusion: TOR was an effective and safe antiestrogens and antiumor agent in postmenopausal patients with advanced breast cancer.

关 键 词：药物疗法 法乐通 乳腺癌 副作用 

分 类 号：R737.905[医药卫生—肿瘤] R979.1[医药卫生—临床医学]